Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17744881 | 0.90 | FADS1 (0.72) | FADS1PTGS1MEN1KMT2AP2RX1 | |
| SCHEMBL9810110 | 0.85 | ALDH1A1 (0.72) | FADS1PTGS1MEN1KMT2AP2RX1 | |
| SCHEMBL3138011 | 0.84 | HDAC4 (0.55) | FADS1PTGS1LMNAMEN1KMT2A | |
| SCHEMBL5668126 | 0.84 | FADS1 (0.65) | FADS1PTGS1MEN1KMT2AP2RX1 | |
| SCHEMBL259352 | 0.84 | MEN1 (0.72) | FADS1PTGS1LMNAMEN1KMT2A | |
| SCHEMBL31424193 | 0.84 | MEN1 (0.72) | FADS1PTGS1LMNAMEN1KMT2A | |
| SCHEMBL4372468 | 0.83 | P2RX1 (0.71) | FADS1LMNAMEN1KMT2AP2RX1 | |
| SCHEMBL1140055 | 0.83 | PTGS1 (0.68) | FADS1PTGS1LMNAMEN1KMT2A | |
| SCHEMBL472983 | 0.83 | FADS1 (0.78) | FADS1PTGS1LMNAMEN1KMT2A | |
| SCHEMBL5666409 | 0.83 | P2RX1 (0.70) | FADS1PTGS1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3558950-B1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | OLIGOMERIX, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3558950-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118791-A9 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| WO-2018118791-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| CN-103130696-B | Anthranilamide compound as well as preparation method and application thereof | UNIV SHANDONG | 2014-06-11 | — | — | CN | disclosed |
| US-5922887-A | NOVEL DELTA OPIOD MODULATORS FOR THE TREATMENT OR PROPHYLAXIS OF PAIN, ORGAN TRANSPLANT REJECTION, DIARRHEA, EPILEPTIC SEIZURES, NEUROLOGICAL DISEASES, AND OTHER DISORDERS | SMITHKLINE BEECHAM SPA (IT) | 1999-07-13 | — | — | US | disclosed |
| US-4642322-A | Stabilization of chlorine-containing thermoplastics with nitrogen-containing organic compounds | CIBA-GEIGY CORPORATION (US) | 1987-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | FADS1 2374/4885PTGS1 2483/4885LMNA 1094/4885 |
| US-11472776-B2 | Quinazolinones that inhibit the formation of tau oligomers and their method of use | MAPT, PSEN1, APP | FADS1 2371/4885PTGS1 2232/4885LMNA 822/4885 |
| US-20240158357-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | FADS1 2374/4885PTGS1 2483/4885LMNA 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.